Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To determine the effect of weight on doxorubicin and cyclophosphamide plasma clearance in
participants who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I
obese (BMI 25-34.9 kg/m2), or class II-III obese (BMI ≥ 35 kg/m2). The hypothesis is that
participants who weigh more will have higher doxorubicin and cyclophosphamide clearances than
participants who weigh less. Restated, the area under the drug-concentration time profile,
also known as the AUC, in participants will decrease as participant weight increases.